YM155, a Novel Survivin Suppressant, Improves the Antitumor Effect of Rituximab and Rituximab-Containing Regimens in Diffuse Large B Cell Lymphoma (DLBCL) Xenograft Mouse Models

被引：0
|
作者：
Nakata, Mari [1 ]
Nakahara, Takahito [1 ]
Kita, Aya [1 ]
Mitsuoka, Keisuke [1 ]
Yamanaka, Kentaro [1 ]
Kaneko, Naoki [1 ]
Miyoshi, Sosuke [1 ]
Mori, Masamichi [1 ]
Koutoku, Hiroshi [1 ]
Sasamata, Masao [1 ]
机构：
[1] Astellas Pharma Inc, Drug Discovery Res, Tsukuba, Ibaraki, Japan
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1064 / 1064
页数：1
相关论文
共 50 条
  • [1] Effect of YM155, a potent survivin suppressant, on the antitumor effect of rituximab in diffuse large B-cell lymphoma (DLBCL) xenograft models: FLT-/FDG-PET imaging studies.
    Mitsuoka, K.
    Miyoshi, S.
    Kita, A.
    Yamanaka, K.
    Nakata, M.
    Murakami, Y.
    Noda, A.
    Jitsuoka, M.
    Fushiki, H.
    Nishimura, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Tumor regression induced by YM155, a novel, survivin suppressant, in human diffuse large B-cell lymphoma models
    Kaneko, Naoki
    Kita, Aya
    Nakahara, Takahito
    Nakata, Mari
    Koutoku, Hiroshi
    Sasamata, Masao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 260P - 260P
  • [3] Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Kaneko, Naoki
    Mitsuoka, Keisuke
    Amino, Nobuaki
    Yamanaka, Kentaro
    Kita, Aya
    Mori, Masamichi
    Miyoshi, Sosuke
    Kuromitsu, Sadao
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1814 - 1822
  • [4] YM155: a small molecule survivin suppressant with potent antitumor effect in human cancer xenograft models
    Kita, Aya
    Nakahara, Takahito
    Takeuchi, Masahiro
    Kinoyama, Isao
    Matsuhisa, Akira
    Yamanaka, Kentaro
    Nakata, Mari
    Kaneko, Naoki
    Koutoku, Hiroshi
    Sasamata, Masao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 32P - 32P
  • [5] A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
    Cheson, Bruce D.
    Bartlett, Nancy L.
    Vose, Julie M.
    Lopez-Hernandez, Andres
    Seiz, Amanda L.
    Keating, Anne T.
    Shamsili, Setareh
    CANCER, 2012, 118 (12) : 3128 - 3134
  • [6] Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL)
    Cheson, B. D.
    Vose, J. M.
    Bartlett, N. L.
    Lopez, A.
    Van der Jagt, R. H.
    Tolcher, A. W.
    Weisenburger, D. D.
    Seiz, A. L.
    Shamsili, S.
    Keating, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] YM155, a novel survivin suppressant, induced downregulation of survivin and potent antitumor activities in experimental human prostate tumor xenograft models.
    Nakahara, T
    Takeuchi, M
    Isao, K
    Tsuyoshi, M
    Akira, M
    Kita, A
    Tominaga, F
    Yamanaka, K
    Sasamata, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9082S - 9083S
  • [8] YM155, a small molecule survivin suppressant, sensitizes human B-cell non-Hodgkin lymphoma to rituximab-induced apoptosis
    Kaneko, Naoki
    Kita, Aya
    Mori, Masamichi
    Sengoku, Takanori
    CANCER RESEARCH, 2012, 72
  • [9] Combination of YM155, a survivin suppressant with a STAT3 inhibitor: A new strategy to treat diffuse large B-cell lymphoma
    Kaneko, Naoki
    Kita, Aya
    Yamanaka, Kentaro
    Mori, Masamichi
    LEUKEMIA RESEARCH, 2013, 37 (09) : 1156 - 1161
  • [10] YM155, a novel small molecule survivin suppressant, exhibits curative antitumor activities in experimental human malignant lymphoma models in vivo
    Kita, A.
    Nakahara, T.
    Yamanaka, K.
    Koutoku, H.
    Takeuchi, M.
    Kinoyama, I.
    Matsuhisa, A.
    Sasamata, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 116 - 116
12345